Since our works demonstrate that myosin inhibitors PClP and PBrP target intracellular trafficking of TGF-β receptors and inhibit TGF-β signaling, these inhibitors could be developed into a broad-spectrum therapeutic agent to treat TGF-β-mediated tissue fibrosis and cancer. Here, MYH14 is linked to cancer.